SDAI Limited Q1 2026: Financial Analysis & Investor Insight
SDAI Limited, listed on the Catalist board of the SGX-ST, has released its unaudited condensed interim financial statements for the first quarter ended 31 March 2026. The report provides a detailed view of the company’s financial health, performance trends, and operational highlights. Below is a structured analysis for investors and financial professionals.
Key Financial Metrics and Performance Table
| Metric | Q1 2026 | Q4 2025 | Q1 2025 | YoY Change | QoQ Change |
|---|---|---|---|---|---|
| Revenue | S\$95,320 | (not disclosed) | S\$44,508 | +114.3% | N/A |
| Gross Profit | S\$62,223 | (not disclosed) | S\$23,438 | +165.6% | N/A |
| Net Loss | S\$945,295 | (not disclosed) | S\$729,798 | +29.5% (higher loss) | N/A |
| EPS (Basic/Diluted) | -0.22¢ | (not disclosed) | -0.17¢ | (more negative) | N/A |
| Net Asset Value/Share | -2.44¢ | -2.22¢ | -2.25¢ | N/A | Decline |
| Dividend (per share) | None | None | None | No change | No change |
Historical Performance and Trends
- Revenue Growth: Q1 2026 revenue more than doubled YoY, mainly from improved sales in the distribution and retail segment.
- Losses: Despite higher revenue and gross profit, net losses increased by almost 30% YoY due to higher selling, distribution, legal, and professional fees, as well as increased salaries and depreciation.
- Negative Equity: Total equity remains negative and worsened to S\$11.27 million in Q1 2026, reflecting continued accumulated losses.
- Working Capital: Negative working capital improved from S\$10.50 million to S\$0.41 million due to loan reclassifications, but liquidity remains a concern.
Exceptional Items and Events
- Legal and Regulatory Matters: The company continues to address legacy issues, including audit qualifications, regulatory inquiries, and potential legal actions. Letters of demand and regulatory disclosures have been made, but outcomes remain uncertain.
- Corporate Actions: Multiple loan renewals and extensions were completed in Q1 2026, pushing maturities to 2027. These include interest-free and redeemable loans with equity conversion options.
- Business Expansion: SDAI launched a proprietary skincare line and entered into strategic partnerships and joint ventures in biotechnology and wellness (notably moxibustion products).
Chairman’s Statement
“No dividend has been declared or recommended by the Directors for 1Q2026 as the Group incurred a loss for 1Q2026 and continues to report accumulated losses as at 31 March 2026.”
The tone is cautious, reflecting ongoing losses and the absence of dividends.
Directors’ Remuneration
- Directors’ fees for Q1 2026 amounted to S\$62,500, consistent with the prior year.
Significant Events Affecting Business
- Trading Suspension: Trading remains suspended since July 2021 due to unresolved audit and regulatory issues.
- Special Audit & Remediation: Internal control weaknesses are being addressed, following phase two of a special audit and regulatory directives from SGX RegCo.
- Legal Action: The company has issued letters of demand and made disclosures to regulators regarding past consultancy services and potential Employment Act infringements.
- Strategic Cooperation: New partnerships in biotechnology and wellness announced in May 2026 may drive future growth.
Corporate Actions & Fund Flows
- No share buybacks, placements, or dilution reported this quarter.
- Multiple loans were extended and restructured, now maturing in late 2027. Loans contain equity conversion options, but fair value deemed insignificant.
- No related party transactions or asset sales/divestments disclosed for Q1 2026.
Forecasts and Outlook
- Industry Trends: Residential projects and traditional distribution are expected to slow, but new healthcare and biotech business lines may provide growth opportunities.
- Risks: Ongoing legal, regulatory, and liquidity risks continue to weigh on the business.
- Liquidity: Cash position improved marginally, but negative working capital and equity persist.
Conclusion & Investor Recommendation
Overall Performance: The company’s Q1 2026 report shows a significant increase in revenue and gross profit, but a continued increase in net losses, negative equity, and working capital. The outlook remains weak due to persistent structural and regulatory risks, ongoing trading suspension, and lack of dividend payouts. While new business initiatives and strategic partnerships offer potential upside, they are at an early stage and have not yet offset legacy issues.
- If you are currently holding SDAI Limited shares: Consider maintaining a cautious stance. Monitor developments regarding regulatory clearance, legal outcomes, and progress in new business lines. The trading suspension and ongoing losses pose substantial risks. Unless material improvements are announced, risk management may warrant a review of your position.
- If you are not holding SDAI Limited shares: It may be prudent to remain on the sidelines until the company resolves its audit qualifications, regulatory issues, and demonstrates sustained profitability or positive cash flow. Watch for key milestones in business turnaround and regulatory compliance before considering an investment.
Disclaimer: This analysis is based solely on the data disclosed in SDAI Limited’s Q1 2026 financial report. It does not constitute investment advice. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
